SCHEMBL5460533

SCHEMBL5460533

Cc1ccc(C(=O)Nc2ccc3[nH]c4c(c3c2)CCCC4NC2CCCCC2)c(C)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RB1 P06400 6/20 0.52
▸ GAA P10253 1/20 0.49
▸ CASP6 P55212 1/20 0.49
▸ KDM4E B2RXH2 2/20 0.48
▸ ALDH1A1 P00352 2/20 0.48
▸ RAB9A P51151 2/20 0.48
▸ SIRT1 Q96EB6 3/20 0.48
▸ RECQL P46063 1/20 0.47
▸ SIRT2 Q8IXJ6 1/20 0.47
▸ BRD3 Q15059 1/20 0.45
▸ PRMT5 O14744 1/20 0.44
▸ MAPT P10636 3/20 0.43
▸ ALOX15 P16050 2/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ MAPK1 P28482 1/20 0.43
▸ ACKR3 P25106 1/20 0.42
▸ CDKN1A P38936 1/20 0.42
▸ GLA P06280 2/20 0.42
▸ KMT2A Q03164 2/20 0.42
▸ MEN1 O00255 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5456607 0.85 GAA (0.49) RB1GAACASP6SIRT1RECQL
SCHEMBL5452147 0.84 RB1 (0.57) RB1RAB9ABRD3MAPTALOX15
SCHEMBL5467883 0.84 SIRT1 (0.48) RB1KDM4EALDH1A1RAB9ASIRT1
SCHEMBL4163723 0.83 RB1 (0.69) RB1GAACASP6SIRT1RECQL
SCHEMBL5449914 0.82 RB1 (0.56) RB1GAACASP6SIRT1RECQL
SCHEMBL5456655 0.82 RB1 (0.56) RB1GAACASP6BRD3PRMT5
SCHEMBL5466568 0.82 RB1 (0.58) RB1SIRT1BRD3MAPTALOX15
SCHEMBL5460471 0.82 RB1 (0.58) RB1GAACASP6SIRT1BRD3
SCHEMBL5461886 0.81 RB1 (0.53) RB1GAACASP6RAB9ABRD3
SCHEMBL5468135 0.81 RB1 (0.55) RB1GAACASP6BRD3PRMT5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070276009-A1 Compositions and Methods for Viral Inhibition CHIRON CORPORATION 2007-11-29 — — US disclosed
US-20070276009-A1 Compositions and Methods for Viral Inhibition CHIRON CORPORATION 2007-11-29 — — US disclosed
US-20070276009-A1 Compositions and Methods for Viral Inhibition CHIRON CORPORATION 2007-11-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070276009-A1 Compositions and Methods for Viral Inhibition MAVS, SARS1, ZC3HAV1 RB1 1821/4885GAA 1417/4885CASP6 3264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback